Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report issued on Tuesday,Benzinga reports. They currently have a $50.00 price target on the stock.

A number of other brokerages have also weighed in on AARD. Royal Bank of Canada began coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an “outperform” rating and a $21.00 target price for the company. Morgan Stanley assumed coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price objective for the company. Finally, Bank of America boosted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, March 27th.

Aardvark Therapeutics Stock Up 10.4 %

NASDAQ:AARD opened at $8.29 on Tuesday. Aardvark Therapeutics has a 1 year low of $6.79 and a 1 year high of $19.58.

Insiders Place Their Bets

In related news, CEO Tien-Li Lee acquired 16,542 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nelson Sun bought 10,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the purchase, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.